Migraine Drugs Market Analysis Report By Therapeutic Class (Triptans, CGRP-based Therapies, Ditans, Neurotoxins, NSAIDs), By Treatment, By Route of Administration, And Segment Forecasts, 2018 - 2025

Published: Sep, 2018 | Pages: 98 | Publisher: Grand View Research
Industry: Pharmaceutical | Report Format: Electronic (PDF)

The global migraine drugs market size is expected to be valued at USD 7.7 billion by 2025, as per a new report by Grand View Research, Inc., exhibiting an 18.0% CAGR during the forecast period. The market is largely driven by factors such as rise in disease prevalence, development of novel therapies, lifestyle changes, and hormonal medications.

Migraine is a debilitating neurological disease characterized by recurrent attacks of severe throbbing head pain that can last for more than three days. Migraine pain may get worse on movement, preventing the patient from carrying out normal, day-to-day activities. In about one-third of attacks, both sides of the head, face, or neck are affected.

Over the past five years, the global migraine drugs market has been relatively stagnant, with the market mainly dominated by usage of generic triptans and other off-label drugs. Majority of the currently prescribed drugs for both acute and preventative treatment are associated with poor efficacy and an unfavorable side-effect profile.

Launch of Amgen/ Novartis' CGRP mAb Aimovig is the first step toward revolutionizing the treatment paradigm of migraine prevention. For drug manufacturers likely to enter the market by 2019, such as Eli Lilly, Teva Pharma, and Alder BioPharma, pricing will be a key differentiating factor as all CGRP-based therapies have a similar efficacy and safety profile.

Further key findings from the report suggest:

• Germany leads the European market, driven by rising disease prevalence, novel drug launches, and increase in R&D activities

• The acute migraine treatment market will be supported by rapid uptake of novel drug classes such as CGRP receptor antagonists and ditans currently under active investigation in multiple Phase II/III trials

• Biohaven's rimegepant is expected to face competition from Allergan's ubrogepant, which has shown superior efficacy in Phase III trials compared to rimegepant

• Eli Lilly's Phase III 5-HT1F receptor agonist Lasmiditan is expected to be a novel first-line non triptan acute treatment option for patients in whom triptans are contradicted

• Approximately 20% of patients seeking preventive treatment for migraine do not respond to available generic medications. Several biologics and small molecules drugs are undergoing active development to target high unmet needs in the preventive treatment segment

• Drugs with novel targets in early-phase development include AOBiome Therapeutics' AOB-203 (antibacterial), Winston Pharma's Dolorac (histamine H1 receptor antagonists), NeuroAxons' NXN-188 (combination of NOS inhibitor and a triptan), and Biohaven's BHV-3500 (gepant). These novel agents are under evaluation for both episodic and chronic migraine in multiple Phase I/II trials.

 Table of Contents

Chapter 1 Report Scope
                 1.1 Treatment Scope
                 1.2 Therapeutic Class Scope
                 1.3 Mode of Administration Scope
                 1.4 Country Scope
                 1.5 Estimates and Forecast Timeline

Chapter 2 Methodology
                 2.1 Research Methodology
                     2.1.1 Information procurement
                 2.2 Information or Data Analysis
                 2.3 Market Formulation & Validation
                 2.4 List of Sources
                 2.5 List of Abbreviations

Chapter 3 Executive Summary

Chapter 4 Disease Primer and Epidemiology
                 4.1 Disease Primer
                     4.1.1 Stages and symptoms
                     4.1.2 Types
                         4.1.2.1 Episodic migraine
                         4.1.2.2 Chronic migraine
                         4.1.2.3 Migraine with Aura
                         4.1.2.4 Migraine without Aura
                         4.1.2.5 Other Forms
                     4.1.3 Causes
                     4.1.4 Risk Factors
                     4.1.5 TRIGGERS
                 4.2 Epidemiology
                     4.2.1 Epidemiological Forecast For Migraine For Seven Major Markets (U.S., Japan, Eu5)

Chapter 5 Global Migraine Market Overview
                 5.1 Introduction and Market Overview
                     5.1.1 Acute treatment
                         5.1.1.1 Triptans
                         5.1.1.2 Ergot Alkaloids
                         5.1.1.3 Non - specific drugs
                     5.1.2 Preventive/ Prophylactic treatment
                 5.2 Market, by Treatment
                 5.3 Market, by Therapeutic Class
                 5.4 Market Size and Forecast by Country (2017 - 2025)
                     5.4.1 Sales Performance by geographic markets, in $ million, 2017 - 2025
                     5.4.2 U.S.
                     5.4.3 Japan
                     5.4.4 U.K.
                     5.4.5 Germany
                     5.4.6 France
                     5.4.7 Spain
                     5.4.8 Italy
                 5.5 Market Share Distribution, by Company (2017 - 2025)
                     5.5.1 Acute Migraine treatment, share distribution by company
                     5.5.2 Preventive Migraine treatment, share distribution by company
                 5.6 Market Dynamics and Brand Strategies
                 5.7 Patent Expiry Schedule
                 5.8 Migraine Drugs Market: Drivers and Restraints
                     5.8.1 Market Drivers and trends
                     5.8.2 Market Restraints
                 5.9 M&A, Deal Landscape (2014 - 2018 YTD)
                     5.9.1 Mergers & Acquistitions
                     5.9.2 Deals landscape
                 5.10 Emerging Markets
                 5.11 Pricing & Reimbursement
                 5.12 SWOT

Chapter 6 Migraine Drugs Market: Pipeline Intelligence
                 6.1 Pipeline Landscape
                     6.1.1 Leading Drugs in Development
                 6.2 Key R&D Trends
                     6.2.1 Calcitonin gene - related peptide (cgrp) targeting therapies
                         6.2.1.1 cgrp monoclonal antibodies
                         6.2.1.2 CGRP small molecule antagonists: Gepants
                     6.2.2 serotonin - 5ht1f receptor agonists: ditans
                     6.2.3 others
                 6.3 Pipeline Landscape
                     6.3.1 late stage pipeline analysis
                 6.4 Clinical Profiles of Disruptive Drugs
                     6.4.1 Epitinezumab (Alder biopharma)
                     6.4.2 Rimegepant (biohaven)
                     6.4.3 AMG - 301 (Amgen)
                     6.4.4 GLObal pipeline forecast

Chapter 7 Company Profiles
                 7.1 Allergan
                     7.1.1 Company Overview
                     7.1.2 Current Product Portfolio
                     7.1.3 Product Forecast Sales up to 2025
                     7.1.4 Strategic Initiatives
                         7.1.4.1 Key Company News Flow
                     7.1.5 Pipeline analysis and overview
                         7.1.5.1 Catalysts & events Calendar
                     7.1.6 SWOT
                 7.2 Amgen
                     7.2.1 Company Overview
                     7.2.2 Current Product Portfolio - 
                     7.2.3 Product Forecast Sales up to 2025
                     7.2.4 Strategic Initiatives
                         7.2.4.1 Key Company News Flow
                     7.2.5 Pipeline analysis and overview
                         7.2.5.1 Catalysts & events Calendar
                     7.2.6 SWOT
                 7.3 Pfizer
                     7.3.1 Company Overview
                     7.3.2 Current Product Portfolio - 
                     7.3.3 Product Forecast Sales up to 2025
                     7.3.4 Strategic Initiatives
                         7.3.4.1 Key Company News Flow
                     7.3.5 SWOT
                 7.4 GlaxoSmithKline
                     7.4.1 Company Overview
                     7.4.2 Current Product Portfolio - 
                     7.4.3 Product Forecast Sales up to 2025
                     7.4.4 Strategic Initiatives
                         7.4.4.1 Key Company News Flow
                     7.4.5 SWOT
                 7.5 Eli Lilly
                     7.5.1 Company Overview
                     7.5.2 Current Product Portfolio
                     7.5.3 Product Forecast Sales up to 2025
                     7.5.4 Strategic Initiatives
                         7.5.4.1 Key Company News Flow
                         7.5.4.2 Catalysts & events Calendar
                     7.5.5 SWOT
                 7.6 Teva Pharma
                     7.6.1 Company Overview
                     7.6.2 Current Product Portfolio - 
                     7.6.3 Product Forecast Sales up to 2025
                     7.6.4 Strategic Initiatives
                         7.6.4.1 Key Company News Flow
                         7.6.4.2 Catalysts & events Calendar
                     7.6.5 SWOT

Chapter 8 Market Outlook
                 8.1 Winners and Losers
                     8.1.1 Winners
                     8.1.2 Losers
                 8.2 Emerging Companies/ New Technology Platforms
                     8.2.1 Alder biopharma
                     8.2.2 Biohaven Pharma
                     8.2.3 AOBiome therapeutics
                     8.2.4 Allodynic therapeutics
                     8.2.5 zosano pharma
                 8.3 What the Future Holds

List of Tables

Table 1 List of Abbreviation
Table 2 Forecast Migraine Prevalence, 2017 - 2025
Table 3 Triptans for Acute Migraine Treatment
Table 4 Ergot Alkaloids, NSAIDs, and others for Acute Migraine Treatment
Table 5 First - line, Second - line, and Third - line Therapies for Migraine Prevention
Table 6 Sales by Treatment, in $ Million, 2017 - 2025
Table 7 Sales Performance by Geographic Markets, in $ Million
Table 8 Migraine Drugs Patent Expiry Schedule
Table 9 Annual Cost Associated with Migraine Treatment, by Country ($ Billion)
Table 10 Pricing of Currently Available Therapies for Migraine
Table 11 Migraine R&D Pipeline - by Phase
Table 12 R&D Pipeline Overview
Table 13 Late stage Pipeline Analysis
Table 14 Epitinezumab
Table 15 Rimegepant
Table 16 AMG - 301
Table 17 Pipeline Forecast
Table 18 Product Profile: Botox (onabotulinumtoxinA)
Table 19 Allergan Product Forecast Sales (2017 - 2025)
Table 20 Allergan Pipeline Analysis and Overview
Table 21 Allergan - Catalysts & Events Calendar
Table 22 Product Profile: Aimovig (erenumab)
Table 23 Amgen Product Forecast Sales (2017 - 2025)
Table 24 Amgen Pipeline Analysis and Overview
Table 25 Amgen - Catalysts & Events Calendar
Table 26 Product Profile: Relpax/ Relpert
Table 27 Pfizer Product Forecast Sales (2017 - 2025)
Table 28 Product Profile: Treximet (Sumatriptan + Naproxen Sodium)
Table 29 Product Profile: Amerge (naratriptan)
Table 30 Product Profile: Imitrex (sumatriptan succinate)
Table 31 Efficacy Comparison - Treximet Vs. Imitrex
Table 32 GlaxoSmithKline Product Forecast Sales (2017 - 2025)
Table 33 Product Profile: Galcanezumab
Table 34 Galcanezumab Phase III EVOLVE - I and EVOLVE - II Study
Table 35 Galcanezumab Phase III REGAIN Study
Table 36 Product Profile: Lasmiditan
Table 37 Galcanezumab - Phase III SAMURAI Study
Table 38 Galcanezumab - Phase III SPARTAN Study
Table 39 Eli Lilly Product Forecast Sales (2017 - 2025)
Table 40 Eli Lilly - Catalysts & Events Calendar
Table 41 Product Profile: Fremanezumab
Table 42 Fremanezumab - Phase III HALO (Chronic Migraine) CM Study
Table 43 Fremanezumab - Phase III HALO (Episodic Migraine) EM Study
Table 44 Teva Product Forecast Sales (2017 - 2025)
Table 45 Teva - Catalysts & Events Calendar

List of Figures

Fig.1 Stages and Symptoms of Migraine
Fig.2 Migraine Types
Fig.3 U.S. - Age and Gender - Specific Migraine Prevalence
Fig.4 Japan - Age and Gender - Specific Migraine Prevalence
Fig.5 U.K. - Age and Gender - Specific Migraine Prevalence
Fig.6 Germany - Age and Gender - Specific Migraine Prevalence
Fig.7 Spain - Age and Gender - Specific Migraine Prevalence
Fig.8 Italy - Age Specific Migraine Prevalence
Fig.9 Global Migraine Market Share, by Treatment (2017 - 2025)
Fig.10 Market Segmentation and Scope
Fig.11 Migraine Market Share, by Therapeutic Class (2017 - 2025)
Fig.12 Migraine Market Share, by Country (2017 & 2025)
Fig.13 U.S. Migraine Drugs Market, $ Million (2017 - 2025)
Fig.14 Japan Migraine Drugs Treatment Market, $ Million (2017 - 2025)
Fig.15 U.K. Migraine Drugs Market, $ Million (2017 - 2025)
Fig.16 Germany Migraine Drugs Market, $ Million (2017 - 2025)
Fig.17 France Migraine Drugs Market, $ Million (2017 - 2025)
Fig.18 Spain Migraine Drugs Market, $ Million (2017 - 2025)
Fig.19 Italy Migraine Drugs Market, $ Million (2017 - 2025)
Fig.20 Acute Migraine Market Shares Distribution, by Company (2017 & 2025)
Fig.21 Migraine Prevention Market Shares Distribution, by Company (2017 & 2025)
Fig.22 Migraine Drugs Market Sector SWOT
Fig.23 Migraine R&D Pipeline
Fig.24 Migraine R&D Pipeline, by Therapeutic Class
Fig.25 Allergan Migraine Sales Forecast
Fig.26 Allergan SWOT
Fig.27 Aimovig Migraine Sales Forecast
Fig.28 Amgen SWOT
Fig.29 Pfizer Migraine Sales Forecast
Fig.30 Pfizer SWOT
Fig.31 GlaxoSmithKline Migraine Sales Forecast
Fig.32 GlaxoSmithKline SWOT
Fig.33 Eli Lilly Migraine Sales Forecast
Fig.34 Amgen SWOT
Fig.35 Teva Migraine Sales Forecast
Fig.36 Teva SWOT